Special Issue "Mitochondrial Drugs for Neurodegenerative Diseases"

Guest Editor
Dr. P. Hemachandra Reddy
Neurogenetics Laboratory, Neuroscience Division, Oregon National Primate Research Center, West Campus, Oregon Health and Science University, 505 N.W., 185th Avenue Beaverton, OR 97006, USA
E-Mail:
Phone: +1 503 418 2625 (office); +1 503 418 2627 (lab)
Fax: +1 503 418 2501
Interests: aging; neurodegenerative diseases; gene expression analysis; transgenic mouse models; mitochondrial biology; mitochondrial function/dysfunction; mitochondrial therapeutics; mitochondrial dynamics

Dear Colleagues,

Mitochondria, cytoplasmic organelles found in virtually every eukaryotic cell, are essential for life and death. In the last two decades tremendous progress has been made in mitochondrial research and has provided significant findings to link mitochondrial dysfunction in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease. Further, recently, several groups developed mitochondrial-targeted antioxidants and tested in cell and mouse models of neurodegenerative diseases. The purpose of this special issue is to assess the current status of mitochondrial therapeutics, particularly mitochondrially targeted molecules in aging and age-related neurodegenerative diseases, and also to discuss the issues related to the development of molecules that cross blood brain barrier, reach mitochondria and protect mitochondria from the toxicity of mutant proteins and other toxic insults.

Prof. Dr. P. Hemachandra Reddy
Guest Editor

Submission Information

All papers should be submitted to pharmaceuticals@mdpi.com. To be published continuously until the deadline and papers will be listed together at the special issue website.

Submitted papers should not have been published nor be under consideration for publication elsewhere. All papers are refereed through a peer-review process. A guide for authors is available on the Instructions for Authors page. Pharmaceuticals is a new international, peer-reviewed, quarterly open access journal published by MDPI.

Article Processing Charges (APC) for publication in this open access journal are waived for well-prepared manuscripts submitted by 30 June 2010. English correction or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those paper accepted for publication, that require extensive additional formatting and/or English corrections.

• Mitochondria
• Aging
• Neurodegenerative Disease
• Mitochondrial-targeted antioxidants
• Cyclophilin D
• Mitochondrial permeability pore
• Alzheimer\'s Disease
• Parkinson\'s Disease
• Calcium Dyshomeostasis